ELDN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	306 044
Average Volume	71 929.00
Market Cap	48.15M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.210
ATR14	$0.0200 (1.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-02	Robinson James A. Jr.	Buy	150 437	Stock Option (Right to Buy)
2023-10-02	Kirk Allan	Buy	150 437	Stock Option (Right to Buy)
2023-10-01	Robinson James A. Jr.	Buy	0
2023-10-02	Kirk Allan	Buy	0
2023-05-05	Bvf Partners L P/il	Buy	3 084 090	Warrants to Purchase Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 17 704 764 \| Sell: 1 858 032

Volume Correlation

Long: -0.12 (neutral)

Short: -0.27 (neutral)

Signal:(59.055) Neutral

Eledon Pharmaceuticals, Correlation

10 Most Positive Correlations
GLPG	0.883
HAIN	0.848
NSTG	0.845
ONEM	0.844
RMRM	0.842
CLLS	0.841
FREQ	0.833
SOPA	0.832
MLAB	0.825
AIHS	0.825

10 Most Negative Correlations
ACLS	-0.87
RDI	-0.865
INOD	-0.859
DMAC	-0.851
SPSC	-0.849
IESC	-0.846
CTLP	-0.845
NVTS	-0.844
VRRM	-0.84
ALOR	-0.84

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eledon Pharmaceuticals, Correlation - Currency/Commodity

-0.18
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.28
( neutral )

0.47
( neutral )

0.59
( weak )

Eledon Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-374 000 (0.00 %)
EPS:	$-1.640

Q4	2023
Revenue:	$0
Gross Profit:	$-94 000.00 (0.00 %)
EPS:	$-0.400

Q3	2023
Revenue:	$0
Gross Profit:	$-94 000.00 (0.00 %)
EPS:	$-0.350

Q2	2023
Revenue:	$0
Gross Profit:	$-94 000.00 (0.00 %)
EPS:	$-0.400

Financial Reports:

No articles found.

Eledon Pharmaceuticals,

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.